Cyxone forms a subsidiary in Switzerland
Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company has initiated registration of Cyxone Switzerland AG, a wholly-owned subsidiary in Switzerland. The subsidiary, which is to be located in Basel, is an important step in strengthening the company’s global presence and opens up for a wider reach of international investments and collaborations.
Kjell G. Stenberg, CEO of Cyxone, commented: “Establishing Cyxone Switzerland AG gives a clear signal of Cyxone’s future growth ambitions. Switzerland is the home of a number of well-established life science and Big Pharma companies and we look forward to the new opportunities that may open through this new subsidiary.”
Cyxone is currently in the process of submitting the necessary documentation to the federal register of commerce in Switzerland. The company’s headquarters will remain in Malmö, Sweden.
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
221 22 Malmö, Sweden
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in a preclinical program and Rabeximod for RA in clinical phase II-program. Cyxone’s Certified Adviser on the Nasdaq First North is Mangold Fondkommission AB, +46 (0)8-503 015 50, firstname.lastname@example.org. www.cyxone.com